Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (35019)	11/1/1998 1:13:00 PM
From: accountclosed	Read Replies (2) \| Respond to of 132070

Thanks for the answer MB. My second question passed yours in the mail, and I think you already answered it. I do think it is an interesting general proposition whether one is "already long the market" with other exposures to the economy. I doubt many financial planners would look at the hardware store owner and say, "Well since your hardware store makes you long the market, you should buy 200,000.00 in oex puts".

To: Knighty Tin who wrote (35019)	11/1/1998 3:51:00 PM
From: novice investor	Read Replies (1) \| Respond to of 132070

Hi Michael, Well, I'm still interested to hear your opinions on Pathogenesis (PGNS). It has broken through its all time high and hit 44 1/2, then it lost 4 1/2 Friday to settle at 40. I still have my March calls and am wondering if this is good time to sell off and switch to puts. NI

To: Knighty Tin who wrote (35019)	11/2/1998 2:26:00 AM
From: upanddown	Read Replies (3) \| Respond to of 132070

Mike, Must be about 150 posts this weekend and an appalling number of them have absolutely nothing to do with investments. In an attempt to get back on track a little and away from philosophical ruminations, doctor-lawyer spats (yawnnnnn!!!) and real estate seminars, I've got a question for you. >>And I still believe my 90/10 strategy, most of which I ripped off from mentors and even people who didn't like me, is the best generator of capital gains at super low risk, in the world.<< If this is the best way to make capital gains, why have a separate capital gains portfolio ? Is that only for plays that you expect will take longer than 6 months (I know you hate LEAPS !) and/or are not optionable ? Thanks, John

To: Knighty Tin who wrote (35019)	11/2/1998 5:26:00 AM
From: flickerful	Read Replies (1) \| Respond to of 132070

michael.... i have been meaning to reply with some background on imclone, in my opinion one of the more promising biotechs. [ they even have cash to sustain them through the year 2000, according to recent sec filings.] beyond a viable pipeline, with demonstrated efficacy for 2 solid new drugs at phase II plus, they have always shown strong insider buying, primarily at or above its present price. i would love to hear your take on them.. here's a recent graph, and their most recent press release...[ be advised jim mcCamant claims they are likely to soon announce a european partnership for development and distribution of C225...i find his rumorsless than compelling, although it has accounted for some recent buying, no doubt. that, i imagine , in addition to a generally renewed interest in the alleged leaders of this down trodden sector.] tscn.com ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ImClone Systems Reports Data on Cancer Therapeutic, C225, at Annual Meeting of the American Society for Therapeutic Radiation and Oncology NEW YORK, NY--(BW HealthWire)--October 27, 1998--ImClone Systems Incorporated (NASDAQ: IMCL) today reported data at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) for the Company's lead cancer therapeutic, C225, an inhibitor of the epidermal growth factor receptor (EGFr). The data, presented by a research team headed by Francisco Robert, M.D.and Director of the Comprehensive Cancer Center University of Alabama at Birmingham, demonstrates that combination treatment using C225 and radiotherapy resulted in 100 percent tumor regression in 14 of 16 patients enrolled in a Phase Ib/IIa trial for the treatment of squamous cell head and neck cancer. One additional patient experienced greater than 50 percent tumor regression, while the 16th patient has not had post treatment follow-up for assessment of response. "We believe these findings show a positive potential clinical benefit for patients with head and neck cancer," commented Harlan W. Waksal, M.D., Executive Vice President and Chief Operating Officer of ImClone Systems. "While recent published data for radiotherapy alone have shown about a 30 to 40 percent response rate in this patient population, this early data for C225 demonstrates a major response rate of 100 percent in a majority of patients. We hope that Phase III clinical studies will further expand and validate these findings." ImClone Systems' lead cancer therapeutic, C225, is a monoclonal antibody that inhibits activity of the epidermal growth factor receptor (EGFr) associated with cancer cell growth in squamous cell carcinoma, renal cell carcinoma, pancreatic carcinoma and other solid tumors. Based on trial results reported at this year's ASCO meeting and at this year's ASTRO meeting, the Company is currently finalizing protocols for two separate Phase III studies using C225 in head and neck squamous cell cancers in combination with chemotherapy and in combination with radiation therapy. ImClone Systems has two oncology products in late stage clinical development and is advancing earlier drug candidates to the clinical stage. In addition to C225, ImClone's other late stage clinical development program is an anti-cancer vaccine, BEC2. ImClone and its corporate partner, Merck KGaA, are initiating a Phase III multinational trial to study BEC2 in small cell lung cancer patients. In preclinical research, the Company is evaluating the therapeutic potential of its anti-FLK-1/KDR monoclonal antibody as an anti-angiogenic agent, especially against tumors known to secrete vascular endothelial growth factor. ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders. Except for the historical information contained herein, the matters discussed in this document may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. The Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: ImClone Systems Incorporated Andrea F. Rabney Senior Director of Corporate Development and Investor Relations (212) 645-1405 Burns McClellan, Inc. Jonathan M. Nugent (investors) Justin Jackson (media) (212) 213-0006